Nurix Therapeutics/NRIX

$16.74

-1.42%
-
1D1W1MYTD1YMAX

About Nurix Therapeutics

Nurix Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of small molecules and antibody therapies based on the modulation of cellular protein levels as a treatment approach for cancer, inflammatory conditions and other diseases. It DELigase is an integrated discovery platform, to identify and advance drug candidates targeting E3 ligases. Its drug candidates include NX-2127, NX-5948 and NX-1607. NX-2127 is an orally bioavailable Brutons tyrosine kinase (BTK) degrader that also degrades cereblon neosubstrates IKZF1 (Ikaros) and IKZF3 (Aiolos) for the treatment of relapsed or refractory B-cell malignancies. NX-5948 is an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and potentially autoimmune diseases. NX-1607 is an oral clinical-stage small molecule drug candidate that inhibits Casitas B-lineage lymphoma proto-oncogene-B (CBL-B).

Ticker

NRIX

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Arthur Sands

Employees

284

Headquarters

San francisco, United States

NRIX Metrics

BasicAdvanced
$822.78M
Market cap
-
P/E ratio
-$2.65
EPS
2.00
Beta
-
Dividend rate
$822.78M
1.99769
$18.12
$4.22
890.42K
2.864
-42.39%
-65.37%
-54.58%
10.172
4.874
4.876
94.02%
24.9%
62.87%

What the Analysts think about NRIX

Analyst Ratings

Majority rating from 11 analysts.
Buy

Price Targets

Average projection from 10 analysts.
43.97% upside
High $35.00
Low $10.00
$16.74
Current price
$24.10
Average price target

NRIX Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-251.51% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$16.5M
9.27%
Net income
$-41.5M
-0.95%
Profit margin
-251.51%
-9.36%

NRIX Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 5.24%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.45
-$0.68
-$0.77
-$0.76
-
Expected
-$0.56
-$0.76
-$0.57
-$0.80
-$0.80
Surprise
-19.64%
-10.03%
35.09%
-5.24%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Nurix Therapeutics stock?

Nurix Therapeutics (NRIX) has a market cap of $822.78M as of April 14, 2024.

What is the P/E ratio for Nurix Therapeutics stock?

The price to earnings (P/E) ratio for Nurix Therapeutics (NRIX) stock is 0 as of April 14, 2024.

Does Nurix Therapeutics stock pay dividends?

No, Nurix Therapeutics (NRIX) stock does not pay dividends to its shareholders as of April 14, 2024.

When is the next Nurix Therapeutics dividend payment date?

Nurix Therapeutics (NRIX) stock does not pay dividends to its shareholders.

What is the beta indicator for Nurix Therapeutics?

Nurix Therapeutics (NRIX) has a beta rating of 2. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

What is the Nurix Therapeutics stock price target?

The target price for Nurix Therapeutics (NRIX) stock is $24.1, which is 43.97% above the current price of $16.74. This is an average based on projections from 10 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Nurix Therapeutics stock

Buy or sell Nurix Therapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing